Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation (Nasdaq: BRKR) announced significant multi-year contracts valued at approximately $50 million with its majority-owned RI Research Instruments GmbH and Bruker Energy & Supercon Technologies (BEST). These contracts involve supplying key technology components for major fusion projects in Europe and Asia. The projects include providing Inner Vertical Targets for the ITER fusion initiative and high-current density RRP® superconductors for a tokamak project. This advancement positions Bruker to play a vital role in future sustainable energy solutions.
Kiyatec Inc. has successfully closed its Series C funding round, raising US$18 million led by new investor Bruker (BRKR) and supported by LabCorp (LH) and others. The funds will enhance the adoption of Kiyatec's clinical testing and preclinical pharma services, vital for improving cancer treatment outcomes. Kiyatec's 3D-Predict™ Glioma test has shown significant clinical correlations, allowing better therapy selection for glioblastoma patients. The company aims to grow its revenue through innovative testing and drug development partnerships.
Bruker Corporation (Nasdaq: BRKR) has signed a definitive agreement to acquire Neurescence Inc., known for its innovative Multiscopes™ technology that allows simultaneous multi-region optical neuroimaging. Neurescence's Chromatone™ system, which minimizes weight on animals, enhances the investigation of neuron functions. This acquisition strengthens Bruker's portfolio in animal imaging and expands its capabilities in neuroresearch. Financial terms of the deal were not disclosed, but the acquisition is expected to leverage synergies with Bruker's existing products, positioning the company as a leader in this field.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend of $0.05 per share, which will be paid on December 16, 2022. The record date for shareholders is December 1, 2022. This decision reflects Bruker’s commitment to returning value to its investors while continuing to manage risks and uncertainties outlined in its SEC filings. The company specializes in high-performance scientific instruments and solutions aimed at improving life science and diagnostics.
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of Inscopix, a leader in miniaturized microscopes for neuroscience research. Inscopix's innovative equipment has been deployed in 600+ institutions globally, facilitating advances in understanding neurological disorders. This acquisition is expected to enhance Bruker's in-vivo imaging capabilities, combining high-resolution multiphoton microscopy with Inscopix’s advanced miniaturized technology. Inscopix's projected FY 2022 revenue is $20-25 million, with expectations of continued double-digit growth.
Bruker Corporation (Nasdaq: BRKR) will participate in the 2022 Jefferies London Healthcare Conference on November 15, 2022, at 12:00 PM Eastern Time. Gerald Herman, Executive VP & CFO, will present and engage in a Q&A session. A live audio webcast will be accessible on the Company's Investor Relations website, with a replay available for 90 days.
Bruker specializes in high-performance scientific instruments and analytical solutions, enabling breakthroughs in life sciences and diagnostics.
Bruker Corporation (Nasdaq: BRKR) reported Q3 2022 revenue of $638.9 million, a 4.9% increase year-over-year, with organic growth at 12.7%. GAAP EPS rose to $0.59, and non-GAAP EPS increased 4.8% to $0.66. The company raised its FY 2022 guidance for organic revenue growth to 8%-10%, up from 7%-9%, while non-GAAP operating margin guidance was also increased to 60-90 bps. Additionally, Bruker's backlog and high-demand products contributed to a strong financial outlook despite currency translation headwinds of 8%.
Bruker Corporation (Nasdaq: BRKR) will release its Q3 2022 financial results on November 3, 2022, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and business trends. Investors can participate via webcast or telephone, with an option to pre-register for expedited entry. A replay of the call will be available until December 3, 2022. Bruker focuses on providing high-performance scientific instruments and solutions, enhancing research in life sciences and diagnostics.
Bruker Corporation (NASDAQ: BRKR) has launched the nanoElute® 2 nano-LC system and updated software for MetaboScape® and TASQ® at IMSC 2022. The new nanoElute® 2 enhances single-cell proteomics with improved chromatography performance and user interface. MetaboScape 2023 introduces advanced metabolic profiling features and quality assessment tools. The MALDI HiPLEX-IHC workflow enables multiplex imaging for protein targets, enhancing spatial localization. These innovations support research in proteomics and protein interactions, significantly advancing capabilities in the scientific community.
Bruker Corporation has unveiled groundbreaking advancements in NMR technology at the ICMRBS 2022 Conference. Their new 8 mm 15N TROSY Cryoprobe improves sensitivity for studying larger proteins and disordered proteins, doubling the sensitivity of earlier models. Additionally, the 160 kHz Ultra-fast spinning MAS probe enhances solid-state NMR analysis, facilitating research on neurodegenerative diseases. Bruker also announced the installation of the 1.2 GHz Avance™ NMR at the University of Lille, expanding research capabilities in structural biology across France.